Pharmaceutical companies use computerized applications in manufacturing, laboratories, quality management, clinical operations, supply chain, and other regulated processes. However, the testing of all functions with the same intensity does not necessarily make these systems safer or more compliant.
The risk of a formatting preference in an internal dashboard is not as high as a calculation affecting a product release. Small interface problems cannot be subjected to the same level of testing as functionality that governs electronic records, laboratory findings, or manufacturing choices. This is why contemporary GxP application testing must be risk-based.
Risk-based testing focuses validation and assurance effort on the functionality most critical to patient safety, product quality, data integrity, and regulatory compliance. Rather than generating excessive documentation for each system functionality, pharmaceutical organizations can apply more rigor to high-risk functionality and disproportionate assurance to low-risk areas.
This method can enhance compliance and testing efficiency with companies adopting LIMS, MES, ERP, eQMS, cloud applications, laboratory platforms, or new AI-enabled systems.
Risk-based GxP application testing is a strategy whereby the scope, method, and intensity of testing depend on the proposed purpose of the application and the impact of system failure.
The goal is not merely to decrease testing. It is to do the right testing of the right level of rigor.
The teams first determine which functions can influence regulated outcomes. The resources available to test can then be focused on those areas, and the less risky functionality can be assured according to its impact.
An empirical evaluation involves the following questions:
Such questions pose a better base of regulated systems testing as compared to the application of the same validation template to all applications.
Conventional validation programs can become documentation-intensive. Teams can generate huge volumes of scripted tests because that is how past systems were tested, not because of what evidence the new application actually requires.
It is pointless to test everything the same way and gain little extra confidence. Less attention can be given to critical functionality, as there is a spread of resources over low-risk features.
A completed test script does not necessarily indicate system quality. When teams focus on writing documents instead of testing the system, testing can become a compliance exercise rather than an assurance process.
Red-tape scripts and duplicated approvals and documentation may create bottlenecks near go-live. This becomes especially problematic when undertaking large digital transformation programs with various GxP applications.
Suppliers may already have considerable testing and development evidence in commercial applications. The repetition of all the activities of suppliers internally without considering its appropriateness may lead to duplication that is not matched with the value of compliance.
Hours spent retesting low-risk functionality are hours that could be spent exploring complex workflows, integrations, data integrity controls, security permissions, calculations, and other important areas.
Risk-based testing is not to be equated with less compliance. When done properly, it can enhance assurance by concentrating resources on functions where failure is most critical.
Functions that affect patient-related decisions should be tested more thoroughly and supported with stronger evidence than administrative functions that do not have significant GxP effects.
Depending on the consequences, manufacturing calculations, laboratory results, electronic approvals, batch-related workflows, and other quality-critical functionality can be tested accordingly.
Applications that generate, process, alter, transfer, or store regulated records must be tested to verify pertinent data integrity controls, such as permissions, audit trails, interfaces, and record handling.
A documented risk assessment provides a rational explanation for why certain functionality received a certain level of testing. This makes the overall GxP system validation plan easier to understand and justify.
Experienced testers and subject matter experts can focus on complex, high-risk functionality instead of spending time on repetitive, low-value tasks.
Effective risk-based pharmaceutical application testing begins before testing. Requirements, intended use, risk assessment, supplier knowledge, and testing strategy must align.
The organization must have a clear idea of why the application is being implemented, by whom it will be used, what processes it will support and what decisions or records are regulated by it.
Teams cannot be confident in what functionality is critical without knowing what they intend to do with it.
Not all features of a GxP application are equally important for regulatory purposes. Teams are expected to identify functionality related to patient safety, product quality, data integrity, or controlled business processes.
To be relevant, consider what might fail and what the results would be. The evaluation must address the impact, probability (where relevant), controls in place, and the capability to detect failure before it causes damage.
Higher-risk functions typically require more rigorous testing and stronger evidence. Less formal testing can be used where appropriate to assure lower-risk functionality. The testing procedure should be based on risk, not organizational custom.
Before undertaking tests, teams must decide on what is acceptable system performance. Clear criteria avoid subjective decisions when results are already available.
Test the application in real-life conditions with suitable data, users, settings, workflows, and failure cases. What actually took place during execution should be evidenced.
Evaluate unresolved defects, deviations, limitations, and residual risks before go-live to confirm the system is suitable for regulated use.
A simple risk-based model helps teams avoid applying the same test strategy to every function.
| Functional Risk | Example | Testing Approach |
| High | Product release calculation | Rigorous testing |
| High | Critical electronic approval | Strong documented evidence |
| Medium | Controlled GxP workflow | Targeted testing |
| Medium | System interface | Relevant integration testing |
| Lower | Non-critical display setting | Proportionate assurance |
The real classification procedure should be based on the organization’s procedures and system context. The key rule is that risk should be commensurate to testing effort.
The industry has been reinforced by Computer Software Assurance to focus on critical thinking and risk-based assurance.
CSA testing motivates organizations to focus assurance on software features and functions that may result in significant risk, rather than using a large number of automatically generated and documented scripts.
This may include choosing alternative test approaches based on risk and system familiarity, and maintaining suitable evidence.
The first thing teams should do is determine what needs assurance and why. The resulting evidence must be documented and not prescribe the whole testing strategy.
Exploratory or scenario-based methods may be useful to build confidence in appropriate functionality, with appropriate risk and relevant procedures, without needless step-by-step scripts.
Testing can be informed by supplier evaluation and available evidence. Depending on the intended use, configuration, and GxP risk, organizations can decide what further assurance is needed.
CSA invites teams to learn how software is used in practice and base assurance activities on key workflows and potential failures.
Various applications have varied risk profiles. One testing strategy cannot be simply duplicated in all technologies.
Testing can focus on sample identification, calculations, specifications, result entry, approvals, interfaces, audit trails, and controlled modifications of laboratory data.
Key points may include manufacturing processes, electronic batch records, material controls, equipment interaction, process parameters, calculations, and electronic approvals.
Testing can cover document control, deviations, CAPA, change control, training, approvals, audit trails, workflows, and electronic records.
GxP-relevant testing may include material status, inventory controls, batch information, master data, interfaces, permissions, and regulated supply-chain processes.
The test strategies must put into consideration configuration, supplier responsibility, integrations, access controls, data handling, upgrades and change management.
AI adds considerations such as data quality, model performance, intended use, human oversight, explainability where applicable, change management, and continuous monitoring.
A risk-based approach is ineffective when organizations adopt the language of risk without changing how they make assurance decisions.
When all requirements are critical, prioritization becomes useless. Risks should be clearly differentiated.
The objective is stronger assurance, not fewer tests. High-risk functionality can even be subjected to stricter testing than in a generic approach.
The testing strategy should be shaped by risk from the outset. It is pointless to complete the test package and then assign risk.
Technical teams may not be aware of all regulated consequences, but they may know the software. Risk assessment and test design should involve process owners and subject matter experts.
System risk can change due to major configuration changes, integrations, upgrades, or new intended uses. When major changes occur, re-evaluate testing decisions.
To shift from documentation-based validation to efficient, risk-based assurance, professionals with knowledge of technology and pharmaceutical compliance are needed.
Pharma Connections offers GxP software testing and validation services to pharmaceutical and life sciences companies that deploy, upgrade, or remediate regulated computerized systems.
Support can be aligned with GxP application testing, risk-based testing, CSV, CSA testing, GxP system validation, software assurance testing, validation documentation, and audit and inspection readiness requirements.
Instead of addressing all application features, Pharma Connections can support testing strategies based on intended use, system functionality, GxP impact, and risks identified.
Companies that move from traditional CSV to modern software assurance methods can access professionals knowledgeable in both traditional validation practices and risk-based CSA.
Pharma Connections can be used to extend internal teams with companies in temporary resource crunches, with large implementations, validation backlogs or specialized projects.
Risk assessments, test evidence, traceability, and validation decisions must be readable and justifiable. Pharma Connections helps companies prepare GxP applications for audits and inspections by regulatory agencies.
Pharma Connections also educates professionals in CSV, CSA, GxP software testing, risk-based validation, documentation, and newer trends like AI validation.
The training focuses on practical skills professionals can apply when seeking validation opportunities with pharmaceutical companies, MNCs, CROs, consulting organizations, and other life sciences employers.
Additional testing does not necessarily produce a more compliant computerized system.
Good GxP application testing focuses on what matters most and provides adequate evidence that critical functionality can be used reliably for its intended regulated use.
Risk-based testing helps pharmaceutical organizations focus assurance efforts on functions that can impact patient safety, product quality, data integrity, and regulatory compliance. When combined with clear requirements, meaningful risk assessment, appropriate testing methods, supplier knowledge, and robust lifecycle controls, it can improve compliance and project efficiency.
To strengthen their strategy, Pharma Connections supports GxP software testing, CSV, CSA testing, risk-based software assurance, validation resources, staff augmentation, audit and inspection readiness, and new AI validation needs.
For professionals, Pharma Connections offers practical validation training to build the technical and compliance capabilities employers in the pharmaceutical and life sciences need today.
GxP application testing tests computerized system functions and controls to determine confidence that an application is functioning as intended and supporting regulated pharmaceutical or life sciences processes.
Risk-based testing uses the potential impact of software failure to set testing effort, focusing more assurance on functions that could impact patient safety, product quality, data integrity, or regulatory compliance.
CSA emphasizes critical thinking, intended use, risk-based assurance, the right testing method, and meaningful evidence, more than just blindly using a large amount of scripted documentation to cover every possible function.
Some systems, including LIMS, MES, eQMS, ERP, EDMS, laboratory applications, clinical platforms, cloud solutions, and AI-enabled applications, may need appropriate GxP validation and testing depending on their intended use.
Yes. Pharma Connections assists pharmaceutical and life sciences companies in GxP application testing, CSV, CSA, risk-based software testing, validation resources, staff augmentation, audit preparedness, and associated validation services.
Pharmaceutical validation workloads change rapidly. An internal team with normal operations can find themselves in…
QMS for Pharma Managers has become a key specialization, with pharmaceutical firms placing greater emphasis…
A GxP application may appear technically ready to release, yet cause severe problems once it…
The field of AI validation is quickly becoming a professional discipline, with pharmaceutical organizations using…
Call/WhatsApp : +91 - 86608 77518
Email: info@pharmaconnections.in
Pharma Connections (A Product of Eduteq Connections Pvt Ltd),
Membership No.: 459, WeWork Salarpuria Symbiosis, Arekere Village, Begur Hobli, Bannerghatta Road, Bengaluru, Karnataka – 560076
Pharma Connections, Established on February 14, 2019, A Product of Eduteq Connections Pvt Ltd (An ISO 9001:2015 certified company), is dedicated to providing training and upskilling opportunities for Life science Professionals.
Read More
